Global Cell Line Development Market Outlook 2031

The global cell line development market is anticipated to grow with a CAGR of 12.39% over the forecast period, i.e., 2022 - 2031. Factors such has growing burden of cancer, and rising need for vaccine production to drive the market growth in the coming years. Additionally, the rising burden of osteoporosis, and also growing risk of coronavirus are expected to boost the market growth. The market estimated to generate revenue of USD 14,600 Million by the end of 2031, up from a revenue of USD 4,500 Million in the year 2021.

The global cell line development market is segmented into numerous segments which include segmentation by product, cell type, application, and by industry. By cell type, the market is segmented into CHO cells, BHK 21 cells, NSO cells, and more. Out of which, BHK 21 cells is anticipated to garner a revenue of USD 2,400 Million by the end of 2031, up from a revenue of USD 700 Million in the year 2021. Furthermore the CHO cells segment is expected to garner the largest revenue of USD 5,400 Million by the end of 2031.

On the basis of region, the global cell line development market is divided into five key regions which includes North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Out of which, the Asia Pacific market is anticipated to generate revenue USD 3,900 Million. A total of $1,100 million was made by the Asia Pacific market in 2021. Additionally, by the end of 2031, the North American market is anticipated to generate USD 5,100 Million in the most revenue.

Some of the prominent industry leaders in the global cell line development market that are included in our report are Lonza Group Ltd., Thermo Fisher Scientific, Corning Incorporated, General Electric Company, Sartorius AG, Selexis SA, Merck KGaA, WuXi AppTec, American Type Culture Collection (ATCC), and European Collection of Authentic Cell Cultures.